Figure 5 from Preclinical Development of T Cells Engineered to Express a T-Cell Antigen Coupler Targeting Claudin 18.2–Positive Solid Tumors
Year: 2025
Type: other
Abstract: Pharmacology of CLDN18.2-TAC T cells in various CLDN18.2-positive tumor mouse models. A, In vivo efficacy of CLDN18.2-TAC T cells against s.c. solid tumors. Tumor volumes of individual animals are shown (n = 5–8/grp). Animals were administered a single i.v. dose of 6 × 106 TAC01-CLDN18.2 or NTD control cells. B, Pharmacokinetics of TAC01-CLDN18.2. NSG mice carrying established s.c. OE19 tumor xenografts were treated with a single i.v. dose of 6 × 106 TAC01-CLDN18.2. Tumor, blood, and stomach samples were collected at various time points, processed to gDNA, and evaluated by TAC-specific ddPCR. Averages and SDs derived from six animals per time point are shown. *, Averages and SDs were derived from only two tumor samples due to tumor clearance in four of six mice. Right, Average tumor volume of mice in the pharmacokinetic study. C, CLDN18.2-TAC T cell efficacy during tumor rechallenge. NSG/MHC-DKO mice engrafted with N87CLDN18.2 tumor xenografts were treated once with 6 × 106 CLDN18.2-TAC T cells (day 0). Two weeks after the primary tumors regressed, mice were rechallenged with N87CLDN18.2 tumor cells given in the opposing hind flank (day 26). Separate groups of mice receiving no treatment were used as negative controls during the first and second tumor challenges. Left, Tumor volumes of individual animals. Right, Mouse body weights relative to day 0. A statistical analysis of efficacy data is shown in Supplementary Table S6. NT, not treated.
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4406227733